Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
NCT Number: NCT07469969
This study is a prospective, multicenter, randomized, controlled, open-label clinical trial designed to evaluate the superiority of transauricular vagus nerve microcurrent stimulation (taVNS) combined with Tailor-Made Notched Music Training (TMNMT) compared with Tinnitus Retraining Therapy (TRT) in patients with chronic subjective tinnitus. A total of 386 participants aged 18-70 years with a tinnitus duration of at least 6 months and a Tinnitus Handicap Inventory (THI) score ≥38 will be enrolled, excluding individuals with severe hearing loss, organic cranial diseases, or other contraindications. Eligible participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group. The control group will receive standardized TRT, including habituation sound therapy and structured educational counseling, while the experimental group will receive TMNMT combined with taVNS (0.1 Hz pulse-train stimulation, sub-pain threshold intensity of 0.5-10 mA). Although the trial is open-label, outcome assessors and statisticians will remain blinded to group allocation. Baseline and follow-up assessments include THI, visual analog scale (VAS), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), audiological evaluations, and multimodal neuroimaging using EEG and fMRI. The primary outcome is the tinnitus improvement response rate at 3 months after treatment initiation, defined as a reduction of more than 7 points in the THI score from baseline. Secondary outcomes include treatment response rates at 6 and 12 months, changes in tinnitus severity and tinnitus-related comorbid symptoms, and neuroplasticity-related changes in central neural mechanisms.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510120, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This group receives combined transcutaneous auricular vagus nerve stimulation (taVNS) and tailor-made notched music training (TMNMT) delivered through a single, registered Class II medical device. The device synchronously administers taVNS (0.1 Hz, pulse train, 0.5-10 mA, titrated below individual pain threshold) and delivers TMNMT via integrated, phase-synchronized algorithms. The notched music is centered at the patient's tinnitus frequency with a ½-octave bandwidth. Treatment consists of 30-minute sessions, four times daily for 3 months.
This group receives standard Tinnitus Retraining Therapy (TRT) using the same device platform, but without active microcurrent output. Therapy includes structured counseling and sound therapy, where broadband natural sounds are delivered at a individually set "mixing" level via the device. Daily sound exposure totals 2 hours over 3 months, supported by initial education and follow-up counseling sessions focused on habituation and cognitive restructuring.
Time frame: Before treatment and at the end of the 3-month treatment period
The Tinnitus Improvement Response Rate is evaluated based on the change in Tinnitus Handicap Inventory (THI) scores. A higher score indicates greater interference of tinnitus with quality of life. Treatment response is defined as a reduction in the THI score of >7 points from the baseline assessment after 3 months of treatment, based on the internationally recognized Minimal Clinically Important Difference (MCID) threshold. Calculation Formula: Tinnitus Improvement Response Rate (%) = (Number of Responders / Total Number of Cases in the Corresponding Group) × 100%
Time frame: Baseline, Month 3, Month 6, Month 12
Patients rate their current perception of tinnitus loudness on a Visual Analogue Scale (VAS) ranging from 0 to 10. A score of 0 represents "extremely faint/imperceptible" tinnitus, and 10 represents "extremely loud/intolerable" tinnitus. The outcome is reported as the change in score from Baseline.
Time frame: Baseline, Month 3, Month 6, Month 12
Based on the pitch characteristics described by the patient, a test stimulus (pure tone or narrow-band noise, 0.125-8.0 kHz) is selected. Using a bracketing procedure with 2 dB steps, the loudness is matched to the patient's tinnitus perception. The outcome is measured in decibels sensation level (dB SL/HL) relative to the patient's hearing threshold.
Time frame: From Baseline through Month 3
Total number of participants who experience treatment-related adverse events. Events include auditory system-related reactions (e.g., burns, earache, hearing deterioration, worsening tinnitus) and non-auditory reactions (e.g., dizziness, headache, palpitations, vomiting) deemed related to the intervention.
Time frame: Baseline, Month 3, Month 6, Month 12
The BAI requires patients to rate 21 anxiety symptoms. The raw score is converted to a standardized score using the formula Y = int(1.19x). Scores range from 0 to 63, with higher scores indicating more severe anxiety. The outcome is reported as the change in standardized score from Baseline.
Time frame: Baseline, Month 3, Month 6, Month 12
The BDI consists of 21 groups of items. Scores are summed to obtain a total score ranging from 0 to 63. Higher scores indicate a more severe degree of depression. The outcome is reported as the change in total score from Baseline.
Time frame: Baseline, Month 3, Month 6, Month 12
The PSQI assesses sleep quality. The Global Score ranges from 0 to 21, where a higher score indicates poorer sleep quality. The outcome is reported as the change in Global Score from Baseline.
Time frame: Month 6, Month 12
Evaluated based on the Tinnitus Handicap Inventory (THI). A "Responder" is defined as a participant showing a reduction in THI score of >7 points from baseline (the Minimal Clinically Important Difference). Reported as the percentage of participants in each group who meet this criterion.
Time frame: Baseline, Month 3, Month 6
Resting-state EEG data will be recorded and analyzed across the broad frequency spectrum (0.5-100 Hz). The outcome measures include: 1) Power Spectral Density (PSD) across global and local regions; 2) Functional connectivity metrics (e.g., Coherence, Phase Lag Index); and 3) Neural network synchronization. Analysis will be performed to assess changes in cortical activity and inhibition/excitation balance.
Time frame: Baseline, Month 3, Month 6
Assessed using resting-state fMRI. Metrics include: 1) Amplitude of Low-Frequency Fluctuations (ALFF) and Regional Homogeneity (ReHo) to reflect local spontaneous brain activity; and 2) Functional Connectivity (FC) strength (z-transformed correlation coefficients) within auditory and non-auditory networks (e.g., Limbic system, Salience network, Default Mode Network).
Time frame: Baseline, Month 3, Month 6
Structural MRI data (T1-weighted images) will be analyzed using Voxel-Based Morphometry (VBM) and surface-based methods. Key metrics include changes in regional Gray Matter Volume (GMV) and Cortical Thickness in tinnitus-related regions (e.g., auditory cortex, prefrontal cortex, hippocampus).
Time frame: Baseline, Month 3, Month 6
Diffusion Tensor Imaging (DTI) will be used to assess white matter integrity and glymphatic function. Metrics include: 1) Fractional Anisotropy (FA) and Mean Diffusivity (MD) of auditory pathways; and 2) The DTI-ALPS (Analysis along the Perivascular Space) index, used as a proxy for measuring glymphatic system activity and waste clearance efficiency.
Contact information is provided by the study sponsor or research team.
Jiahong Li
CONTACT
86+13760870116
Yuexin Cai
CONTACT
86+13825063663
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Other
Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Training Therapy for Chronic Subjective Tinnitus: A Multicenter, Randomized, Controlled, Open-label Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07665385
Chronic Subjective Tinnitus, Ear Diseases
Sohag, Egypt
View Trial DetailsNCT01302873
Chronic Subjective Tinnitus, Ear Diseases
Berlin, Germany
View Trial Details